Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.8412.7000
Address
60-66 Hanover Street Fitzroy, Victoria (VIC) 3065
Description
Genetic Technologies Ltd. engages in the provision of molecular risk assessment tests for cancer. It operates through ,the EasyDNA, AffinityDNA, and GeneType/Corporate segments. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The AffinityDNA segment deals with AffinityDNA branded test sales and expenses. The GeneType/Corporate segment includes the GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.04 - 0.29
Trade Value (12mth)
AU$2,194.00
1 week
2.56%
1 month
-6.98%
YTD
-67.8%
1 year
-79.07%
All time high
77.59
EPS 3 yr Growth
12337.50%
EBITDA Margin
-157.20%
Operating Cashflow
-$10m
Free Cash Flow Return
-144.00%
ROIC
-181.50%
Interest Coverage
-233.40
Quick Ratio
0.80
Shares on Issue (Fully Dilluted)
N/A
HALO Sector
Industrials
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
30 August 24 |
Preliminary Final Report
×
Preliminary Final Report |
30 August 24 |
FY24 results announcement and operations update
×
FY24 results announcement and operations update |
28 August 24 |
Non-Renounceable Issue extension of Closing Date
×
Non-Renounceable Issue extension of Closing Date |
28 August 24 |
Update - Proposed issue of securities - GTG
×
Update - Proposed issue of securities - GTG |
15 August 24 |
Global launch of geneType on EasyDNA platform
×
Global launch of geneType on EasyDNA platform |
12 August 24 |
Eligible shareholders access letter
×
Eligible shareholders access letter |
12 August 24 |
Ineligible shareholders letter
×
Ineligible shareholders letter |
02 August 24 |
Lodgement of Prospectus - Non-renounceable Entitlement Offer
×
Lodgement of Prospectus - Non-renounceable Entitlement Offer |
02 August 24 |
Entitlement Offer Prospectus
×
Entitlement Offer Prospectus |
31 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
26 July 24 |
Strategic restructure to focus on USA sales growth
×
Strategic restructure to focus on USA sales growth |
26 July 24 |
Proposed issue of securities - GTG
×
Proposed issue of securities - GTG |
19 July 24 |
Change in substantial holding
×
Change in substantial holding |
18 July 24 |
Change in substantial holding
×
Change in substantial holding |
16 July 24 |
Appointment of CFO and Company Secretary
×
Appointment of CFO and Company Secretary |
16 July 24 |
Application for quotation of securities - GTG
×
Application for quotation of securities - GTG |
16 July 24 |
S708A Cleansing Notice
×
S708A Cleansing Notice |
12 July 24 |
Change in substantial holding
×
Change in substantial holding |
09 July 24 |
GeneType to Enter Canadian and New Zealand Markets
×
GeneType to Enter Canadian and New Zealand Markets |
28 June 24 |
Business Update - June 2024
×
Business Update - June 2024 |
28 June 24 |
Resignation of CFO and Company Secretary
×
Resignation of CFO and Company Secretary |
25 June 24 |
GeneType identifies 79.5% at risk of serious disease
×
GeneType identifies 79.5% at risk of serious disease |
24 June 24 |
Change in substantial holding
×
Change in substantial holding |
21 June 24 |
GTG Live Investor Webinar and Q&A - June 27
×
GTG Live Investor Webinar and Q&A - June 27 |
18 June 24 |
GTG Expands Operational Capacity in North America
×
GTG Expands Operational Capacity in North America |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.